Immunomodulation Pathogenesis and Treatment of Bone Nonunion

Abstract

Fractures and bone nonunion commonly require surgical intervention. Serious outcomes of non-healing in the late stages of fracture place a significant financial burden on society and families. Bone nonunion occurs when a fracture stops healing, for many reasons, and leads to a variety of bad outcomes. Numerous factors, including biomechanics and immunology, are involved in the complicated mechanisms of bone nonunion. The immune-inflammatory response plays a significant part in the emergence of bone nonunion, and the occurrence, control, and remission of inflammation in the bone healing process have a significant influence on the ultimate success of bone tissue repair. In the bone microenvironment, immune cells and associated cytokines control bone repair, which is significantly influenced by macrophages, T cells, and fibroblast growth factor. To limit acute inflammation and balance osteogenesis and osteoblastogenesis for tissue repair and regeneration, immune cells and various cytokines in the local microenvironment must be precisely regulated. As a bad complication of late-stage fractures, bone nonunion has a significant effect on patients’ quality of life and socioeconomic development. Therefore, in-depth research on its pathogenesis and treatment methods has important clinical value. To provide more precise, focused therapeutic options for the treatment of bone nonunion, we discuss the regulatory roles of the key immune cells engaged in bone healing within the microenvironment during bone healing and their effect on osteogenesis.

Keywords

Bone Nonunion / Immunomodulation / Inflammatory Response / macrophages / T Cells

References

[1] Panteli M, Vun JSH, Pountos I, Howard A, Jones E, Giannoudis PV. Biological and molecular profile of fracture non-union tissue: a systematic review and an update on current insights. J Cell Mol Med. 2022; 26(3): 601–623.

[2] Dozza B, Salamanna F, Baleani M, Giavaresi G, Parrilli A, Zani L, et al. Nonunion fracture healing: evaluation of effectiveness of demineralized bone matrix and mesenchymal stem cells in a novel sheep bone nonunion model. J Tissue Eng Regen Med. 2018; 12(9): 1972–1985.

[3] Megas P. Classification of non-union. Injury. 2005; 36(Suppl 4): S30–S37.

[4] Hodgson H, Giannoudis PV, Howard A. Fracture non-union; what are the current perceived challenges among clinicians? Injury. 2022; 53(12): 3865–3866.

[5] Neumann MV, Zwingmann J, Jaeger M, Hammer TO, Südkamp NP. Non-Union in Upper Limb Fractures—clinical evaluation and treatment options. Acta Chir Orthop Traumatol Cech. 2016; 83(4): 223–230.

[6] Pearson RG, Clement RG, Edwards KL, Scammell BE. Do smokers have greater risk of delayed and non-union after fracture, osteotomy and arthrodesis? A systematic review with meta-analysis. BMJ Open. 2016; 6(11): e010303.

[7] van Basten BM, Houben IB, Blokhuis TJ. The non-union scoring system: an interobserver reliability study. Eur J Trauma Emerg Surg. 2019; 45(1): 13–19.

[8] Lafuente-Gracia L, Borgiani E, Nasello G, Geris L. Towards in silico models of the inflammatory response in bone fracture healing. Front Bioeng Biotechnol. 2021; 9: 703725.

[9] Roberts SJ, Ke HZ. Anabolic strategies to augment bone fracture healing. Curr Osteoporos Rep. 2018; 16(3): 289–298.

[10] Holmes D. Non-union bone fracture: a quicker fix. Nature. 2017; 550(7677): S193.

[11] Aro HT, Wippermann BW, Hodgson SF, Chao EY. Internal remodeling of periosteal new bone during fracture healing. J Orthop Res. 1990; 8(2): 238–246.

[12] Kolar P, Schmidt-Bleek K, Schell H, Gaber T, Toben D, Schmidmaier G, et al. The early fracture hematoma and its potential role in fracture healing. Tissue Eng, Part B. 2010; 16(4): 427–434.

[13] Hoff P, Gaber T, Strehl C, Jakstadt M, Hoff H, Schmidt-Bleek K, et al. A pronounced inflammatory activity characterizes the early fracture healing phase in immunologically restricted patients. Int J Mol Sci. 2017; 18(3): 583.

[14] Haffner-Luntzer M, Heilmann A, Rapp AE, Beie S, Schinke T, Amling M, et al. Midkine-deficiency delays chondrogenesis during the early phase of fracture healing in mice. PLoS One. 2014; 9(12): e116282.

[15] Burska AN, Giannoudis PV, Tan BH, Ilas D, Jones E, Ponchel F. Dynamics of early Signalling events during fracture healing and potential serum biomarkers of fracture non-Union in Humans. J Clin Med. 2020; 9(2): 492.

[16] Thomson DD. Introduction—mechanisms of fracture healing and pharmacologic control. J Musculoskelet Neuronal Interact. 2003; 3(4): 295–296.

[17] Mountziaris PM, Mikos AG. Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng Part B Rev. 2008; 14(2): 179–186.

[18] Geris L, Gerisch A, Sloten JV, Weiner R, Oosterwyck HV. Angiogenesis in bone fracture healing: a bioregulatory model. J Theor Biol. 2008; 251(1): 137–158.

[19] Schlundt C, El Khassawna T, Serra A, Dienelt A, Wendler S, Schell H, et al. Macrophages in bone fracture healing: their essential role in endochondral ossification. Bone. 2018; 106: 78–89.

[20] Goldhahn J, Féron JM, Kanis J, Papapoulos S, Reginster JY, Rizzoli R, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int. 2012; 90(5): 343–353.

[21] Tam WL, Freitas Mendes L, Chen X, Lesage R, Van Hoven I, Leysen E, et al. Human pluripotent stem cell-derived cartilaginous organoids promote scaffold-free healing of critical size long bone defects. Stem Cell Res Ther. 2021; 12(1): 513.

[22] Hak DJ. Management of aseptic tibial nonunion. J Am Acad Orthop Surg. 2011; 19(9): 563–573.

[23] Faienza MF, Chiarito M, D’Amato G, Colaianni G, Colucci S, Grano M, et al. Monoclonal antibodies for treating osteoporosis. Expert Opin Biol Ther. 2018; 18(2): 149–157.

[24] Shapiro F, Wu JY. Woven bone overview: structural classification based on its integral role in developmental, repair and pathological bone formation throughout vertebrate groups. Eur Cell Mater. 2019; 38: 137–167.

[25] Schindeler A, McDonald MM, Bokko P, Little DG. Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol. 2008; 19(5): 459–466.

[26] McKibbin B. The biology of fracture healing in long bones. J Bone Jt Surg Br. 1978; 60-b(2): 150–162.

[27] Wang M, Yang N, Wang X. A review of computational models of bone fracture healing. Med Biol Eng Comput. 2017; 55(11): 1895–1914.

[28] Khanna A, Gougoulias N, Maffulli N. Intermittent pneumatic compression in fracture and soft-tissue injuries healing. Br Med Bull. 2008; 88(1): 147–156.

[29] Wang H, Wei X, Liu P, Fu YH, Wang PF, Cong YX, et al. Quality of life and complications at the different stages of bone transport for treatment infected nonunion of the tibia. Medicine. 2017; 96(45): e8569.

[30] de Seny D, Cobraiville G, Leprince P, Fillet M, Collin C, Mathieu M, et al. Biomarkers of inflammation and innate immunity in atrophic nonunion fracture. J Transl Med. 2016; 14(1): 258.

[31] Horton JE, Raisz LG, Simmons HA, Oppenheim JJ, Mergenhagen SE. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science. 1972; 177(4051): 793–795.

[32] Tsukasaki M, Takayanagi H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol. 2019; 19(10): 626–642.

[33] Okamoto K, Takayanagi H. Osteoimmunology. Cold Spring Harb Perspect Med. 2019; 9: 1.

[34] Song C, Cai W, Liu F, Cheng K, Guo D, Liu Z. An in-depth analysis of the immunomodulatory mechanisms of intervertebral disc degeneration. JOR Spine. 2022; 5(4): e1233.

[35] Song C, Zhou Y, Cheng K, Liu F, Cai W, Zhou D, et al. Cellular senescence—molecular mechanisms of intervertebral disc degeneration from an immune perspective. Biomed Pharmacother. 2023; 162: 114711.

[36] Maruyama M, Rhee C, Utsunomiya T, Zhang N, Ueno M, Yao Z, et al. Modulation of the inflammatory response and bone healing. Front Endocrinol. 2020; 11: 386.

[37] Qin Y, Guan J, Zhang C. Mesenchymal stem cells: mechanisms and role in bone regeneration. Postgrad Med J. 2014; 90(1069): 643–647.

[38] Kapasa ER, Giannoudis PV, Jia X, Hatton PV, Yang XB. The effect of RANKL/OPG balance on reducing implant complications. J Funct Biomater. 2017; 8(4): 42.

[39] Xiong Y, Mi BB, Lin Z, Hu YQ, Yu L, Zha KK, et al. The role of the immune microenvironment in bone, cartilage, and soft tissue regeneration: from mechanism to therapeutic opportunity. Mil Med Res. 2022; 9(1): 65.

[40] Pajarinen J, Lin T, Gibon E, Kohno Y, Maruyama M, Nathan K, et al. Mesenchymal stem cell-macrophage crosstalk and bone healing. Biomaterials. 2019; 196: 80–89.

[41] Loi F, Córdova LA, Zhang R, Pajarinen J, Lin TH, Goodman SB, et al. The effects of immunomodulation by macrophage subsets on osteogenesis in vitro. Stem Cell Res Ther. 2016; 7: 15.

[42] Gibon E, Loi F, Córdova LA, Pajarinen J, Lin T, Lu L, et al. Aging affects bone marrow macrophage polarization: relevance to bone healing. Regen Eng Transl Med. 2016; 2(2): 98–104.

[43] Freytes DO, Kang JW, Marcos-Campos I, Vunjak-Novakovic G. Macrophages modulate the viability and growth of human mesenchymal stem cells. J Cell Biochem. 2013; 114(1): 220–229.

[44] Chang MK, Raggatt LJ, Alexander KA, Kuliwaba JS, Fazzalari NL, Schroder K, et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol. 2008; 181(2): 1232–1244.

[45] Vi L, Baht GS, Whetstone H, Ng A, Wei Q, Poon R, et al. Macrophages promote osteoblastic differentiation in-vivo: implications in fracture repair and bone homeostasis. J Bone Miner Res. 2015; 30(6): 1090–1102.

[46] Schlundt C, Fischer H, Bucher CH, Rendenbach C, Duda GN, Schmidt-Bleek K. The multifaceted roles of macrophages in bone regeneration: a story of polarization, activation and time. Acta Biomater. 2021; 133: 46–57.

[47] Duda GN, Geissler S, Checa S, Tsitsilonis S, Petersen A, Schmidt-Bleek K. The decisive early phase of bone regeneration. Nat Rev Rheumatol. 2023; 19(2): 78–95.

[48] Snyder RJ, Lantis J, Kirsner RS, Shah V, Molyneaux M, Carter MJ. Macrophages: a review of their role in wound healing and their therapeutic use. Wound Repair Regen. 2016; 24(4): 613–629.

[49] Yang N, Liu Y. The role of the immune microenvironment in bone regeneration. Int J Med Sci. 2021; 18(16): 3697–3707.

[50] Zhao Z, Hou X, Yin X, Li Y, Duan R, Boyce BF, et al. TNF induction of NF-κB RelB enhances RANKL-induced Osteoclastogenesis by promoting inflammatory macrophage differentiation but also limits it through suppression of NFATc1 expression. PLoS One. 2015; 10(8): e0135728.

[51] Berardi S, Corrado A, Maruotti N, Cici D, Cantatore FP. Osteoblast role in the pathogenesis of rheumatoid arthritis. Mol Biol Rep. 2021; 48(3): 2843–2852.

[52] Wustrow TP. Biology of interleukin-1 (IL-1), with respect to otorhinolaryngology-head and neck surgery. Head Neck. 1994; 16(1): 88–94.

[53] McKee MD, Pedraza CE, Kaartinen MT. Osteopontin and wound healing in bone. Cells Tissues Organs. 2011; 194(2–4): 313–319.

[54] Ono T, Takayanagi H. Osteoimmunology in bone fracture healing. Curr Osteoporos Rep. 2017; 15(4): 367–375.

[55] Groom JR. Moving to the suburbs: T-cell positioning within lymph nodes during activation and memory. Immunol Cell Biol. 2015; 93(4): 330–336.

[56] Miyajima A, Tanaka M, Itoh T. Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming. Cell Stem Cell. 2014; 14(5): 561–574.

[57] Li J, Tan J, Martino MM, Lui KO. Regulatory T-cells: potential regulator of tissue repair and regeneration. Front Immunol. 2018; 9: 585.

[58] Colburn NT, Zaal KJ, Wang F, Tuan RS. A role for gamma/delta T cells in a mouse model of fracture healing. Arthritis Rheum. 2009; 60(6): 1694–1703.

[59] Aurora R, Silva MJ. T cells heal bone fractures with help from the gut microbiome. J Clin Invest. 2023; 133(8): e167311.

[60] Hu Y, Cui Q, Luo C, Luo Y, Shi J, Huang H. A promising sword of tomorrow: human γδ T cell strategies reconcile allo-HSCT complications. Blood Rev. 2016; 30(3): 179–188.

[61] Dixit M, Singh KB, Prakash R, Singh D. Functional block of IL-17 cytokine promotes bone healing by augmenting FOXO1 and ATF4 activity in cortical bone defect model. Osteoporos Int. 2017; 28(7): 2207–2220.

[62] Pacifici R. The role of IL-17 and TH17 cells in the bone catabolic activity of PTH. Front Immunol. 2016; 7: 57.

[63] Fei Y, Gronowicz G, Hurley MM. Fibroblast growth factor-2, bone homeostasis and fracture repair. Curr Pharm Des. 2013; 19(19): 3354–3363.

[64] Guo YC, Yuan Q. Fibroblast growth factor 23 and bone mineralisation. Int J Oral Sci. 2015; 7(1): 8–13.

[65] Bollenbecker S, Barnes JW, Krick S. Fibroblast growth factor signaling in development and disease. Int J Mol Sci. 2023; 24(11): 9734.

[66] Le Blanc S, Simann M, Jakob F, Schütze N, Schilling T. Fibroblast growth factors 1 and 2 inhibit adipogenesis of human bone marrow stromal cells in 3D collagen gels. Exp Cell Res. 2015; 338(2): 136–148.

[67] Wang J, Liu S, Li J, Yi Z. The role of the fibroblast growth factor family in bone-related diseases. Chem Biol Drug Des. 2019; 94(4): 1740–1749.

[68] Hurley MM, Adams DJ, Wang L, Jiang X, Burt PM, Du E, et al. Accelerated fracture healing in transgenic mice overexpressing an anabolic isoform of fibroblast growth factor 2. J Cell Biochem. 2016; 117(3): 599–611.

[69] Bosetti M, Leigheb M, Brooks RA, Boccafoschi F, Cannas MF. Regulation of osteoblast and osteoclast functions by FGF-6. J Cell Physiol. 2010; 225(2): 466–471.

[70] Xu J, Huang Z, Wang W, Tan X, Li H, Zhang Y, et al. FGF8 signaling alters the osteogenic cell fate in the hard palate. J Dent Res. 2018; 97(5): 589–596.

[71] Hung IH, Schoenwolf GC, Lewandoski M, Ornitz DM. A combined series of Fgf9 and Fgf18 mutant alleles identifies unique and redundant roles in skeletal development. Dev Biol. 2016; 411(1): 72–84.

[72] Wang L, Roth T, Abbott M, Ho L, Wattanachanya L, Nissenson RA. Osteoblast-derived FGF9 regulates skeletal homeostasis. Bone. 2017; 98: 18–25.

[73] Schmid GJ, Kobayashi C, Sandell LJ, Ornitz DM. Fibroblast growth factor expression during skeletal fracture healing in mice. Dev Dyn. 2009; 238(3): 766–774.

[74] Guimarães JM, Guimarães IC, Duarte ME, Vieira T, Vianna VF, Fernandes MB, et al. Polymorphisms in BMP4 and FGFR1 genes are associated with fracture non-union. J Orthop Res. 2013; 31(12): 1971–1979.

[75] Xu W, Luo F, Wang Q, Tan Q, Huang J, Zhou S, et al. Inducible activation of FGFR2 in adult mice promotes bone formation after bone marrow ablation. J Bone Miner Res. 2017; 32(11): 2194–2206.

[76] Chen H, Sun X, Yin L, Chen S, Zhu Y, Huang J, et al. PTH 1-34 ameliorates the osteopenia and delayed healing of stabilized tibia fracture in mice with achondroplasia resulting from gain-of-function mutation of FGFR3. Int J Biol Sci. 2017; 13(10): 1254–1265.

[77] Su N, Yang J, Xie Y, Du X, Lu X, Yin Z, et al. Gain-of-function mutation of FGFR3 results in impaired fracture healing due to inhibition of chondrocyte differentiation. Biochem Biophys Res Commun. 2008; 376(3): 454–459.

[78] Su N, Li X, Tang Y, Yang J, Wen X, Guo J, et al. Deletion of FGFR3 in osteoclast lineage cells results in increased bone mass in mice by inhibiting Osteoclastic bone resorption. J Bone Miner Res. 2016; 31(9): 1676–1687.

[79] Bai J, Ge G, Wang Q, Li W, Zheng K, Xu Y, et al. Engineering stem cell recruitment and Osteoinduction via bioadhesive molecular mimics to improve osteoporotic bone-implant integration. Research. 2022; 2022: 9823784.

[80] Carreira AC, Lojudice FH, Halcsik E, Navarro RD, Sogayar MC, Granjeiro JM. Bone morphogenetic proteins: facts, challenges, and future perspectives. J Dent Res. 2014; 93(4): 335–345.

[81] Van Lieshout EMM, Den Hartog D. Effect of platelet-rich plasma on fracture healing. Injury. 2021; 52(Suppl 2): S58–s66.

[82] Baldwin P, Li DJ, Auston DA, Mir HS, Yoon RS, Koval KJ. Autograft, allograft, and bone graft substitutes: clinical evidence and indications for use in the setting of Orthopaedic trauma surgery. J Orthop Trauma. 2019; 33(4): 203–213.

[83] Madison RD, Nowotarski PJ. The reamer-irrigator-aspirator in nonunion surgery. Orthop Clin North Am. 2019; 50(3): 297–304.

[84] Su JC, Liu XW, Yu BQ, Li ZD, Li M, Zhang CC. Shape memory Ni-Ti alloy swan-like bone connector for treatment of humeral shaft nonunion. Int Orthop. 2010; 34(3): 369–375.

[85] Dreyer CH, Jørgensen NR, Overgaard S, Qin L, Ding M. Vascular endothelial growth factor and mesenchymal stem cells revealed similar bone formation to allograft in a sheep model. Biomed Res Int. 2021; 2021: 6676609.

[86] Yang X, Jiang T, Wang Y, Guo L. The role and mechanism of SIRT1 in resveratrol-regulated osteoblast autophagy in osteoporosis rats. Sci Rep. 2019; 9(1): 18424.

[87] Liang G, Zhao J, Pan J, Yang Y, Dou Y, Yang W, et al. Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs. J Orthop Surg Res. 2023; 18(1): 312.

[88] Murahashi Y, Yano F, Nakamoto H, Maenohara Y, Iba K, Yamashita T, et al. Multi-layered PLLA-nanosheets loaded with FGF-2 induce robust bone regeneration with controlled release in critical-sized mouse femoral defects. Acta Biomater. 2019; 85: 172–179.

[89] Baht GS, Vi L, Alman BA. The role of the immune cells in fracture healing. Curr Osteoporos Rep. 2018; 16(2): 138–145.

RIGHTS & PERMISSIONS

2024 The Author(s). Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.